- Home
- NCNA vs REVB Comparison
NCNA vs REVB Comparison
Compare NCNA & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- REVB
- Stock Information
- Founded
- NCNA 1997
- REVB 2020
- Country
- NCNA United Kingdom
- REVB United States
- Employees
- NCNA N/A
- REVB N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- REVB Health Care
- Exchange
- NCNA Nasdaq
- REVB Nasdaq
- Market Cap
- NCNA 4.5M
- REVB 3.8M
- IPO Year
- NCNA 2017
- REVB N/A
- Fundamental
- Price
- NCNA $0.05
- REVB $2.79
- Analyst Decision
- NCNA Buy
- REVB
- Analyst Count
- NCNA 2
- REVB 0
- Target Price
- NCNA $25.00
- REVB N/A
- AVG Volume (30 Days)
- NCNA 208.6M
- REVB 212.9K
- Earning Date
- NCNA 08-14-2025
- REVB 08-08-2025
- Dividend Yield
- NCNA N/A
- REVB N/A
- EPS Growth
- NCNA N/A
- REVB N/A
- EPS
- NCNA N/A
- REVB N/A
- Revenue
- NCNA N/A
- REVB N/A
- Revenue This Year
- NCNA N/A
- REVB N/A
- Revenue Next Year
- NCNA N/A
- REVB N/A
- P/E Ratio
- NCNA N/A
- REVB N/A
- Revenue Growth
- NCNA N/A
- REVB N/A
- 52 Week Low
- NCNA $0.03
- REVB $2.11
- 52 Week High
- NCNA $10.79
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- NCNA 38.50
- REVB 42.76
- Support Level
- NCNA $0.05
- REVB $2.20
- Resistance Level
- NCNA $0.13
- REVB $2.92
- Average True Range (ATR)
- NCNA 0.02
- REVB 0.27
- MACD
- NCNA 0.00
- REVB 0.26
- Stochastic Oscillator
- NCNA 4.62
- REVB 88.01
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).